BioSpace News Archive

A first-of-its-kind study published in eClinicalMedicine - The Lancet, found that LiverMultiScan-cT1 (an MRI-derived non-invasive tissue biomarker), improved autoimmune hepatitis (AIH) management by identifying patients in biochemical remission as well as patients in deep remission, with undetected, active sub-clinical disease at a high risk of disease relapse.

The Board of Directors has resolved that the Annual General Meeting of Vitrolife AB will take place on Wednesday 27 April 2022 at 4.00 pm.

NuGen Medical Devices Inc., and Unifire, Inc., are pleased to announce they have entered into a Master Distribution and Marketing Agreement dated March 14 2022, whereas Unifire has been granted exclusive rights to sell NuGen M.D.'s needle-free injection device into various US Government agencies.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will present at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2022, in London, England.

Reaction Biology (“Reaction” or the “Company”), an industry- leading provider of drug discovery services, today announced the launch of its In Vitro Evaluation of Safety and Toxicity (InVEST) Panel, an early safety pharmacology tool that detects potential drug toxicity effects that may cause adverse drug reactions and hinder clinical development.

Breast cancer is the leading type of cancer in terms of number of cases and rapid increase in the number of newly diagnosed breast cancer is observed during the past few years.

Global DNA Test Kit Market Opportunity > USD 10 Billion by 2028.

The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and nephrologists) about their choices of imaging and contrast agents in patients with cancer.

Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022.

Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, announced a collaboration with Main Line Health, home to four of the Philadelphia region’s most respected acute care hospitals.